# B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

> **NCT01049633** · — · NO_LONGER_AVAILABLE · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)**

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **BIOLOGICAL:** Allogeneic Pancreatic Islet Cells
- **DRUG:** Sirolimus
- **BIOLOGICAL:** Basiliximab
- **DRUG:** Tacrolimus
- **DRUG:** Antibacterial, Antifungal, and Antiviral Prophylaxis
- **DRUG:** Trimethoprim/sulfamethoxazole
- **DRUG:** Clotrimazole
- **DRUG:** Valganciclovir
- **DRUG:** Heparin
- **DRUG:** Enoxaparin
- **DRUG:** Pentoxifylline
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT01049633
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01049633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01049633, "B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01049633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*